Download PDF
Thromb Haemost 1977; 38(04): 1010-1017
DOI: 10.1055/s-0038-1651919
Original Article
Schattauer GmbH

Depletion of Platelet Amine Storage Granules by the Antithrombotic Agent, Suloctidil

David C. B. Mills
1   Thrombosis Research Center, Temple University Hospital, 3400 North Broad Street, Philadelphia, Pennsylvania, 19140, U.S.A.
,
Donald E. Macfarlane
1   Thrombosis Research Center, Temple University Hospital, 3400 North Broad Street, Philadelphia, Pennsylvania, 19140, U.S.A.
› Author Affiliations
Further Information

Publication History

Publication Date:
04 July 2018 (online)

Also available at
    Permissions and Reprints

Summary

Suloctidil, a compound with antithrombotic properties in animal models, causes depletion of human platelet serotonin stores during 1–5 hr incubation with platelet-rich plasma in vitro. This effect is not attended by leakage of cytoplasmic nucleotides or by alterations in cyclic AMP metabolism, malondialdehyde production or energy balance. 5HT uptake was also inhibited but uptake of adenine was not. 5HT released by suloctidil appeared in the supernatant as oxidation products, though the amine also accumulated when re-uptake was blocked by imipramine.

 

  • References

  • 1 Cazenave J. P, Reimers H. J, Packham M. A, Mustard J. F. 1977; Effect of reserpine on rabbit platelet aggregation and adherence to collagen of injured rabbit aorta. Biochemical Pharmacology 26: 149.
    CrossrefPubMedGoogle Scholar
  • 2 Da Prada M, Bartholini G, Pletscher A. 1965; Effect of monoamine liberators on the metabolism of 5 hydroxytryptamine in blood platelets. Biochemical Pharmacology 14: 1721.
    CrossrefPubMedGoogle Scholar
  • 3 De Gaetano G, Miragliotta G, Roncucci R, Lanse J, Lambelin G. 1976; Suloctidil: A novel inhibitor of platelet aggregation in human beings. Thrombosis Research 8: 361.
    CrossrefPubMedGoogle Scholar
  • 4 De Gaetano G, Roncaglione M. C, Miragliotta G, Wielosz M, Garattini S. 1977; In vitro effects of suloctidil on 14C-5 hydroxytryptamine uptake and liberation in rat platelets. Pharmacological Research Communications 9: 315.
    CrossrefPubMedGoogle Scholar
  • 5 Gurewich V, Lipinski B. 1976; Evaluation of antithrombotic properties of suloctidil in comparison with aspirin and dipyridamole. Thrombosis Research 9: 101.
    CrossrefPubMedGoogle Scholar
  • 6 Haverbach B. J, Dutcher T. F, Shore P. A, Tomich E. G, Terry L. L, Brodie B. B. 1957; Serotonin changes in platelets and brain induced by small daily doses of reserpine: Lack of effect of depletion of platelet serotonin on hemostatic mechanisms. New England Journal of Medicine 256: 343.
    CrossrefPubMedGoogle Scholar
  • 7 Macfarlane D. E, Mills D. C. B. 1975; The effects of ATP on platelets: Evidence against the central role of released ADP in primary aggregation. Blood 46: 309.
    PubMedGoogle Scholar
  • 8 Macfarlane D. E, Gardner S, Lipson C, Mills D. C. B. 1977; Malondialdehyde production by platelets during secondary aggregation. Thrombosis and Haemostasis 38: 1002.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 9 Mills D. C. B, Roberts G. C. K. 1967; Effects of adrenaline on human blood platelets. Journal of Physiology 193: 443.
    CrossrefPubMedGoogle Scholar
  • 10 Mills D. C. B. 1974. The platelet as a point of attack for antithrombotic agents. In: Medicinal Chemistry IV. (ed.) Mass J. Amsterdam: Elsevier; 197.
    Google Scholar
  • 11 Mills D. C. B, Macfarlane D. E. 1975; Cytochalacins: Effects on platelet aggregation, adenylate cyclase and membrane transport processes. Thrombosis et Diathesis Haemorrhagica 34: 917.
    PubMedGoogle Scholar
  • 12 Mills D. C. B, Macfarlane D. E. 1976; Suloctidil: A potential antithrombotic agent. Effects on human platelets in vitro. Federation Proceedings 35: 807.
    PubMedGoogle Scholar
  • 13 Mitchell J. R. A, Sharp A. A. 1964; Platelet clumping in vitro. British Journal of Haematology 10: 78.
    CrossrefPubMedGoogle Scholar
  • 14 Mustard J. F, Rowsell H. C, Smythe H. A, Senyi A, Murphy E. A. 1967; The effect of sulfinpyrazone on platelet economy and thrombus formation in rabbits. Blood 29: 859.
    PubMedGoogle Scholar
  • 15 Nickerson M, Collier B. 1975. In: Pharmacological Basis of Therapeutics. (eds.) Goodman L. S, Gilman A. New York: Macmillan; 557.
    Google Scholar
  • 16 O’Brien J. R. 1964; A comparison of platelet aggregation produced by seven compounds and a comparison of their inhibitors. Journal of Clinical Pathology 17: 275.
    CrossrefPubMedGoogle Scholar
  • 17 Pletscher A, Burkard W. P, Tranzer J. P, Gey K. P. 1967; Two sites of 5 hydroxytryptamine uptake in blood platelets. Life Sciences 6: 273.
    CrossrefPubMedGoogle Scholar
  • 18 Reimers H. J, Allen D. T, Feuerstein I. A, Mustard J. F. 1975; Transport and storage of serotonin by thrombin-treated platelets. Journal of Cell Biology 65: 359.
    CrossrefPubMedGoogle Scholar
  • 19 Roba J, Claeys M, Lambelin G. 1976; Antithrombogenic effects of suloctidil. European Journal of Pharmacology 37: 265.
    CrossrefPubMedGoogle Scholar
  • 20 Roba J, Reuse-Blom S, Lambelin G. 1976; In vivo antispasmodic activity of suloctidil. Archives Internationales de Pharmacodynamie 221: 54.
    PubMedGoogle Scholar